Early stage biotech Werewolf Therapeutics plans IPO (Nasdaq:HOWL)

Werewolf Therapeutics (Nasdaq:HOWL) has filed for an IPO to raise some $100M, although that’s likely just a placeholder figure. The biotech firm has three early stage cancer drugs.
Read More